Gufic BioSciences
- Market cap
- ₹ 3,936 Cr.
- P/E
- 57.9x
- P/B
- 5.94x
- 52-week range
- 268 – 467.8
- ROE
- 10%
- ROCE
- 12%
- Dividend yield
- 0%
- Debt / equity
- 0.61
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Gufic Biosciences Limited is an India-based company, which is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Company operates in the pharmaceutical segment. It has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro M and Zad G; Herbal, including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap and Smashit tablet, and Aesthaderm, including Prosil, Moiseta Face Wash and Revanox Serum. Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products under active pharmaceutical ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole and Everolimus. Its Gufic Stridden includes Irvical and Eve.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Gufic BioSciences against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)57.9 against a typical 34.3: pricier than most peers (1st = cheapest).166th of 220
- Sales growth+15% against a typical +15.6% from a year earlier.101st of 197
- Profit growth+83.3% against a typical +18.9% from a year earlier.37th of 160
- Share price, 3 months+10.9% against a typical −0.5%.60th of 200
- Size₹ 3,935.7 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).59th of 199
Latest announcements
Exchange filings and their impact on the company.
- USFDA issued 3 observations after pre-approval inspection of Indore plant, likely delaying US approvals by a few months.
Gufic Biosciences said the USFDA conducted a pre-approval inspection at its Indore manufacturing facility in Pithampur, Madhya Pradesh from October 15 to October 23, 2026. The inspection ended with 3 observations in Form FDA 483. The company said it will work with the USFDA to address the observations within the stipulated timeframe. With only 3 observations and no warning letter, this points to a short delay in US approvals from the new site rather than disruption to current business.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A- by 2 agencies- All agencies agree and none has raised a warning.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil A- | Stable | 8 Sep 2026 |
| ICRA | [ICRA]A- | Stable | 10 Nov 2025 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 8 Sep 2026 | Reaffirmed | Crisil A- | — | CRISIL | ₹ 516 Cr. | |
| 10 Nov 2025 | Reaffirmed | [ICRA]A- | — | ICRA | ₹ 150 Cr. | |
| 8 Oct 2025 | Reaffirmed | Crisil A- | — | CRISIL | ₹ 425 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 14 Aug 2026 | Financial Results | To consider and approve the unaudited financial results for the quarter ended June 30, 2026 and other business matters |
| 29 May 2026 | Financial Results/Dividend/Other business matters | To consider and approve, inter alia, the Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and financial year ended March 31, 2026, dividend and other business matters |
| 13 Feb 2026 | Financial Results/Other business matters | To consider and approve Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Nine months ended December 31, 2025 and other business matters |
| 14 Nov 2025 | Financial Results/Other business matters | To consider and approve the Unaudited financial results for the Quarter and half year ended September 30, 2025 and other business matters |
| 13 Aug 2025 | Financial Results/Other business matters | To consider and approve the unaudited financial results for the quarter ended Jun 30, 2025 and other business matters |
| 30 May 2025 | Financial Results/Dividend/Other business matters | To consider and approve, inter alia, Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2025, and to recommend a final dividend, if any, for the Financial Year 2024-25. |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 215 | 202 | 195 | 203 | 204 | 208 | 205 | 227 | 230 | 231 | 252 | 261 |
| Expenses | 176 | 165 | 161 | 167 | 166 | 174 | 178 | 195 | 195 | 195 | 206 | 214 |
| Operating Profit | 39 | 36 | 34 | 36 | 39 | 34 | 27 | 32 | 36 | 36 | 46 | 47 |
| OPM % | 18% | 18% | 18% | 18% | 19% | 16% | 13% | 14% | 16% | 16% | 18% | 18% |
| Other Income | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 1 | 2 | 1 | −1 | 0 |
| Interest | 4 | 3 | 4 | 5 | 5 | 5 | 8 | 9 | 10 | 8 | 9 | 9 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 5 | 8 | 8 | 8 | 8 | 8 | 8 |
| Profit before tax | 31 | 30 | 27 | 28 | 29 | 26 | 11 | 16 | 21 | 21 | 28 | 30 |
| Tax % | 25% | 25% | 26% | 26% | 26% | 26% | 26% | 26% | 27% | 26% | 26% | 26% |
| Net Profit | 23 | 22 | 20 | 21 | 22 | 19 | 8 | 12 | 15 | 16 | 21 | 22 |
| EPS in Rs | 2.39 | 2.22 | 2 | 2.08 | 2.17 | 1.93 | 0.79 | 1.2 | 1.49 | 1.55 | 2.05 | 2.24 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 17%
- 5 Years
- 14%
- 3 Years
- 11%
- TTM
- 15%
- 10 Years
- 24%
- 5 Years
- 7%
- 3 Years
- −7%
- TTM
- 20%
- 10 Years
- 26%
- 5 Years
- 16%
- 3 Years
- 15%
- TTM
- —
- 10 Years
- 20%
- 5 Years
- 18%
- 3 Years
- 13%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Gufic BioSciences | ₹ 424.00 | ₹ 3,936 Cr. | 57.9x | 5.9x | 10% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.9x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 74x | 11.6x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 76.4x | 20.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 28x | 3.4x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.3x | 4.3x | 19.7% | 18.5% |
Management
- Jayesh P. Choksi
- Executive Chairman of the Board, Managing Director
- Pranav J. Choksi
- Chief Executive Officer, Whole Time Director
- Devkinandan B. Roonghta
- Chief Financial Officer
- Ami Naresh Shah
- Compliance Officer, Company Secretary
- Pankaj J. Gandhi
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.